Literature DB >> 7097510

High-pressure liquid chromatographic determination of cimetidine in plasma and urine.

G W Mihaly, S Cockbain, D B Jones, R G Hanson, R A Smallwood.   

Abstract

An assay is described for the determination of the H2-receptor antagonist, cimetidine, in human plasma and urine. Alkalinized plasma or urine was extracted with methylene chloride, the organic phase was evaporated, and the reconstituted residue was analysed by high-pressure liquid chromatography (HPLC) using a reversed-phase prepacked plastic column housed in a radial compression module. The metabolite, cimetidine sulfoxide, was identified but could not be quantitated due to interference from the solvent front. The sensitivity limit of the assay was 25 ng/ml. The assay was applied to the measurement of plasma and urine samples in a pilot pharmacokinetic study. Cimetidine was substantially absorbed and rapidly eliminated (plasma elimination half-life of 112-130 min). Plasma cimetidine concentrations could be measured to 12 hr after a 200-mg dose (iv or oral), but they were below the sensitivity of the assay by 24 hr. Urinary excretion of unmetabolized cimetidine accounted for 40-50% of the administered dose in the first 12 hr. This assay is simpler and more sensitive than those previously described, and it is suitable for the measurement of cimetidine in plasma and urine of subjects receiving doses appropriate for clinical use.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097510     DOI: 10.1002/jps.2600710528

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  The influence of duration of intravenous infusion of an acute dose on plasma concentrations of cimetidine.

Authors:  D J Morgan; D A Uccellini; K Raymond; G W Mihaly; D B Jones; R A Smallwood
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics.

Authors:  L K Webster; G W Mihaly; D B Jones; R A Smallwood; J A Phillips; F J Vajda
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Pharmacokinetic studies of cimetidine and ranitidine before and after treatment in peptic ulcer patients.

Authors:  G W Mihaly; D B Jones; J A Anderson; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

4.  Metabolic changes in cimetidine treatment for scald injury on the peritoneo-serosal surface in far-advanced gastric cancer patients treated by intraperitoneal hyperthermic perfusion.

Authors:  S Fujimoto; M Takahashi; K Kobayashi; M Kokubun; R D Shrestha; S Kiuchi; C Konno
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Effect of a 2 g cimetidine infusion on twenty-four-hour intragastric pH in critically ill patients.

Authors:  G Tomé; R Fiasse; M Reynaert; P Mahieu; F Hanssens
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

6.  Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.

Authors:  R Hulhoven; J P Desager; S Cox; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Cimetidine absorption in humans during sucralfate coadministration.

Authors:  R D'Angio; M Mayersohn; K A Conrad; M Bliss
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.